April 07, 2026

Maternal Diabetes and the Hidden Risk of ROP

Retrospective cohort study links maternal diabetes to increased ROP risk in premature infants

The Ophthalmologist

April 07, 2026

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Conexiant

March 31, 2026

Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

Conexiant

March 24, 2026

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Conexiant

March 24, 2026

Artificial Tears Reduce Dryness Symptoms in 1-Month Study

Prospective multicenter study without a control group shows symptom scores reduced by more than half after 4 weeks of treatment

Conexiant

March 01, 2026

Dual-Pathway Gene Therapy for Geographic Atrophy

A new gene therapy approach suggests a potential breakthrough in treating geographic atrophy by combining neuroprotection with complement modulation for more effective vision preservation.

Retinal Physician

June 01, 2014

Indications and Considerations For Chromodissection

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

September 01, 2016

Innovation in Retina

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

October 01, 2016

CODING Q&A

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician